Table 2.
Study characteristics of the subgroup analyses/main study comparing SGLT-2 inhibitors VS placebo in patients with T2DM and HF.
| Study | Intervention | Sample size, n | Age, years# | Female sex, % | Type of HF included | HF status |
|---|---|---|---|---|---|---|
| CANVAS | Canagliflozin | 803 | 64.1 ± 8.3 | 43.1 | Both preserved and reduced | With history of HF, but not known if had existing HF. |
| Placebo | 658 | 63.4 ± 8.3 | 45.9 | |||
| DAPA-HF | Dapagliflozin | 1075 | 66.3 ± 9.9 | 22.3 | Reduced only | Existing HF |
| Placebo | 1064 | 66.7 ± 9.8 | 22.3 | |||
| DECLARE–TIMI 58 | Dapagliflozin | 318/908* | NR | NR | Reduced only | Including existing HF, with history of HF but without existing reduced EF |
| Placebo | 353/1007 | NR | NR | |||
| EMPEROR-Reduced | Empagliflozin | 927 | 66.8 ± 10.0 | 22.7 | Reduced only | Existing HF |
| Placebo | 929 | 66.6 ± 10.3 | 23.5 | |||
| SOLOIST-WHF | Sotagliflozin | 608 | 69 (63-76) | 32.6 | Both preserved and reduced | Diagnosis with HF ≥3 months prior to Screening, and with history of hospitalization for HF |
| Placebo | 614 | 70 (64-76) | 34.9 |
T2DM, type 2 diabetes mellitus; HF, heart failure; NR, not reported; EF, ejection fraction.
*Existing HF only/Combined existing HF and with history of HF.
#Age was presented as mean ± SD or median (interquartile range).